203 / 510
Cuidados
Continuos
202
BIBLIOGRAFÍA
Pharmacology of Cancer Chemotherapy. En Vincent T. DeVita, Jr, Theodore S. Lawrence, Steven
A. Rosenberg, eds. Cancer Principles and Practice of Oncology: Lippincott, Williams & Wilkins
2008; 407-496
Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. MASCC Skin
Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR
inhibitor-associated dermatologic toxicities. Support Care Cancer 2011 19:1079–1095
ESMO Practice Guidelines: management os skin toxicities from EGFR inhibitor therapies. 2009
Allevato M. Efectos adversos cutáneos de la terapia antineoplásica. Act Terap Dermatol 2008;
31: 78
Burton C, Azzi A, Kerridge I. Adverse events after Imatinib Mesylate Therapy. N Engl J Med 2002;
346: 712- 713.
Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of
kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491–500.
Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat
Rev Clin Oncol 2011; 11(2): 91-99.
Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities os RAF inhibitors. Lancet Oncol
2013: 14:e11-18
Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse
effects associated with vemurafenib in patients with metastasic melanoma: practical advice on
diagnosis, prevention and management of the main treatment-related skin toxicities. British J
Dermatology 2012;167:987-994
Wang J, Lu Z, Au JL. Protection against chemotherapy-induced alopecia. PharmRes 2006; 23(11):2505-10.
http://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies
Todas las fichas técnicas de los medicamentos relacionados en el capítulo pueden encontrarse
en: European Medicines Agency.
http://www.ema.europa.eu/docs/en_GB/document_library/